Education and Innovation in Cardiovascular Medicine
News • 26-1-2015

EMA positive opinion for use of liraglutide for treatment of obesity

Based on clinical trial data, a positive opinion is adopted for use of the GLP-1 analogue in addition to adequate diet and physical activity, for weight management in obesity. Read more

Choice of optimal treatment for smoking cessation guided by nicotine metabolite biomarker

26-1-2015 • Lerman C et al., Lancet Respir Med 2015
Treating normal nicotine metabolisers with varenicline and slow metabolisers with nicotine patch could optimise quit rates while minimising side-effects. Read more
News • 23-1-2015

FH_CONNECT launch at ISA2015 in Amsterdam

A new global initiative to be launched in May 2015. The goal of FH-CONNECT is to bring together stakeholders involved in FH, from clinicians, researchers, patients, patient support groups as well as policy makers and industry so that we can improve the care of those affected by FH. Read more

Variation in blood pressure and mean heart rate predict cognitive dysfunction

20-1-2015 • Böhm M et al., Hypertension 2014
In patients with high CV risk, visit-to-visit variation in systolic blood pressure and high resting heart rate were independent predictors of cognitive decline, dysfunction and deterioration. Read more
News • 15-1-2015

Vaccine in development to lower PCSK9

A PCSK9 vaccine should stimulate the body to produce its own PCSK9 antibodies, in an attempt to lower LDL-c levels. An oral PCSK9-inhibitor is also in development. Read more

ARNI stabilises the course of heart failure, substantial effects in addition to recommended therapy

13-1-2015 • Eur Heart J en Circulation 2014
The ARNI LCZ696 can reduce the risk of worsening HF, more so than ACE-inhibition. The benefit of LCZ696 is similar to that of other treatments when compared to placebo, but LCZ696 improves HF on top of background therapy. Read more

New FAMCAT tool helps identify individuals with suspect FH in primary care

8-1-2015 • Weng SF et al., 2015
Using the Clinical Practice Research Datalink, a prediction model for primary care was developed and validated to identify individuals with high probability of having familial hypercholesterolaemia. Read more

Reciprocal regulation PCSK9 and LDL-receptor may explain efficacy of PCSK9-inhibition

21-1-2015 • Tavori H et al., Atherosclerosis 2015
The large LDL-c lowering effect of PCSK9-inhibition may be the consequence of the combination of induction of LDLR degradation by PCSK9 and clearance of the ligand PCSK9 from the circulation via the LDLR receptor. Read more
News • 19-1-2015

Andexanet alfa significantly and immediately reverses anticoagulation effect of rivaroxaban

Phase III ANNEXA-R study tested the efficacy and safety of a universal antidote to factor Xa inhibitors in healthy volunteers. Primary endpoint was met and andexanet alfa was well tolerated. Read more
News • 15-1-2015

Ticagrelor meets primary efficacy endpoint in secondary prevention outcomes trial

Ticagrelor, in addition to low-dose aspirin, was effective in the secondary prevention of atherothrombotic events in patients more than 12 months after a heart attack. Read more

Increased risk of stroke in highly educated individuals with self-reported memory complaints

12-1-2015 • Sajjad A et al., Stroke 2015
Individuals with subjective memory complaints, especially those with a high level of education, showed a higher risk of stroke than those who did not report memory complaints. Read more

Already in young women, healthy lifestyle pays off for long-term health benefits

7-1-2015 • Chomistek et al., J Am Coll Cardiol. 2015
Young women who maintained a healthy lifestyle had substantially lower risk of coronary heart disease and development of CVD risk factors after 20 years of follow-up. Read more